Transaction DateRecipientSharesTypePriceValue
8th May 2020Marco Taglietti6,000Conversion of derivative$0.00
12th December 2019Marco Taglietti166,667Open or private purchase$0.90$150,000.30
21st August 2019Marco Taglietti9,500Open or private purchase$1.11$10,545.00
20th August 2019Marco Taglietti500Open or private purchase$1.11$555.00
15th August 2019Marco Taglietti10,015Open or private purchase$1.01$10,115.15
17th April 2019Marco Taglietti25,000Open or private purchase$1.63$40,750.00
15th February 2019Scott Sukenick100,000Grant/award etc.$0.00
15th February 2019Gonzalez David Angulo150,000Grant/award etc.$0.00
15th February 2019Eric Francois125,000Grant/award etc.$0.00
10th January 2019Marco Taglietti25,000Open or private purchase$0.69$17,250.00
Scynexis logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

SCYNEXIS, Inc. is a biotechnology company. It engages in the development of novel oral and intravenous triterpenoid antifungal.

Ticker: SCYX
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1178253
Employees: 27
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $34 M (0%)
Other Assets, Current: $863 Th (28%)
Assets, Current: $41 M (-22%)
Property, Plant and Equipment, Net: $354 Th (-12%)
Other Assets, Noncurrent: $812 Th (0%)
Assets: $45 M (-20%)
Accounts Payable, Current: $5 M (-32%)
Accrued Liabilities, Current: $2 M (0%)
Liabilities, Current: $7 M (-33%)
Liabilities: $39 M (-12%)
Common Stock, Shares, Issued: $10 M (0%)
Retained Earnings (Accumulated Deficit): $285 M (0%)
Stockholders' Equity (Parent): $6 M (0%)
Liabilities and Equity: $45 M (-20%)
Revenue: $57 Th (-52%)
Research and Development: $8 M (-53%)
Operating Income/Loss: $12 M (-51%)
Other Income, net: $2 M (-70%)
Provision for income taxes: $3 M (0%)